Related Experiment Video
Updated: Mar 29, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
24.8K
Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3
Javier Ampuero1, Manuel Romero-Gómez1
1Unit for the Clinical Management of Digestive Diseases & CIBERehd, Virgen Macarena - Virgen del Rocio University Hospitals, Avenida Manuel Siurot, s/n, Sevilla 41017, Spain.
Gastroenterology Clinics of North America
|November 25, 2015
Summary
Hepatitis C virus (HCV) genotype 3 is now considered difficult to treat, unlike previously thought. New therapies face challenges with relapse rates and optimal treatment duration for genotype 3.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) genotypes 2 and 3 were previously considered easy to treat.
- Sustained virologic responses (SVRs) of up to 80% were achieved with peginterferon and ribavirin for 24 weeks.
Purpose of the Study:
- To investigate the evolving treatment landscape for HCV genotypes.
- To address challenges in treating HCV genotype 3 with new antiviral drugs.
Main Methods:
- Analysis of treatment outcomes for HCV genotypes.
- Evaluation of new drug efficacy and safety profiles.
Main Results:
- HCV genotype 3 is now recognized as the most difficult-to-treat genotype.
- Emerging challenges include managing relapse rates and determining optimal therapy duration.
- Sofosbuvir is a key component of genotype 3 treatment but has limitations in patients with renal impairment (creatinine clearance < 30 mL/min).
Conclusions:
- Treatment strategies for HCV genotype 3 require re-evaluation due to increased difficulty.
- Further research is needed to optimize therapy duration and minimize relapse rates.
- Careful consideration of drug options, like Sofosbuvir, is essential, especially in patients with reduced kidney function.
More Related Videos
Related Concept Videos
01:25Hepatitis
37
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
01:10Retrovirus Life Cycles
50.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
62
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
62
01:30Inhibitors of Viral Protein Synthesis
24
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
01:29Venous Thrombosis III: Interprofessional Care
465
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465